WallStreetZenWallStreetZen

NASDAQ: REVB
Revelation Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Be the first to know when Wall Street analysts revise their REVB stock forecasts and price targets.

Forecast return on equity

Is REVB forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
34.86%

Forecast return on assets

Is REVB forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

REVB revenue forecast

What is REVB's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$34.7M
Avg 2 year Forecast
$34.7M
Avg 3 year Forecast
$73.2M

REVB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
REVB$2.18N/AN/A
VRPX$3.10N/AN/A
ATXI$6.20$56.25+807.26%Strong Buy
CMND$1.16N/AN/A
FNCH$2.32N/AN/A
View Top Biotech Stocks

Revelation Biosciences Stock Forecast FAQ

What is REVB's revenue growth forecast for 2027-2029?

(NASDAQ: REVB) Revelation Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.96%.

Revelation Biosciences's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast REVB's revenue for 2027 to be $56,648,148, with the lowest REVB revenue forecast at $56,648,148, and the highest REVB revenue forecast at $56,648,148. On average, 1 Wall Street analysts forecast REVB's revenue for 2028 to be $56,646,515, with the lowest REVB revenue forecast at $56,646,515, and the highest REVB revenue forecast at $56,646,515.

In 2029, REVB is forecast to generate $119,547,171 in revenue, with the lowest revenue forecast at $119,547,171 and the highest revenue forecast at $119,547,171.

If you're new to stock investing, here's how to buy Revelation Biosciences stock.

What is REVB's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: REVB) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is REVB's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: REVB) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.